InvestSMART

Cogstate Limited (ASX: CGS) - Announcements

Current share price for CGS : $2.590 0.04 (1.52%)+

ASX company news and announcements for Cogstate Limited (CGS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cogstate Limited (CGS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cogstate Limited (CGS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cogstate Limited (CGS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$440 CogState Signs its First Agreement with AstraZeneca 18 Jul 2007 8:30AM $0.175 $2.590 risen by 1,380%
$440 CogState Signs Second Agreement with GlaxoSmithKline 13 Jul 2007 9:20AM $0.200 $2.590 risen by 1,195%
$440 CogState Signs Second Agreement with Merck 9 Jul 2007 11:37AM $0.200 $2.590 risen by 1,195%
$440 Third Quarter Activities & Cashflow Reports 20 Apr 2007 3:17PM n/a $2.590 n/a
$440 Half Yearly Report & Half Year Accounts 22 Feb 2007 1:02PM $0.185 $2.590 risen by 1,300%
$440 Commitments Test Entity - Second Quarter Report 25 Jan 2007 12:22PM $0.220 $2.590 risen by 1,077.27%
$440 Issued US Patent 16 Jan 2007 9:10AM $0.220 $2.590 risen by 1,077.27%
$440 Commitments Test Entity - First Quarter Report 26 Oct 2006 12:11PM $0.180 $2.590 risen by 1,338.89%
$440 Launches real time cognitive data monitoring system 19 Oct 2006 9:36AM $0.210 $2.590 risen by 1,133.33%
$440 Signs its First Agreement with Merck 21 Sep 2006 8:55AM $0.235 $2.590 risen by 1,002.13%
$440 Preliminary Final Report/Full Year Accounts 24 Aug 2006 2:45PM n/a $2.590 n/a
$440 First Agreement with Lundbeck 23 Aug 2006 9:48AM n/a $2.590 n/a
$440 CogState Divests Therapeutic Drug Development Portfolio 21 Aug 2006 10:43AM $0.250 $2.590 risen by 936%
$440 United States Patent Approval 25 Jul 2006 12:26PM $0.200 $2.590 risen by 1,195%
$440 Commitments Test Entity - Fourth Quarter Report 24 Jul 2006 2:11PM $0.200 $2.590 risen by 1,195%
$440 CogState Announces First Contract with GlaxoSmithKline 30 May 2006 9:16AM $0.280 $2.590 risen by 825%
$440 Commitments Test Entity - Third Quarter Report 20 Apr 2006 1:43PM $0.240 $2.590 risen by 979.17%
$440 Signs Distribution Agreement in Japan 15 Mar 2006 11:54AM n/a $2.590 n/a
$440 Non Renounceable Rights Offer Prospectus 23 Feb 2006 8:29AM n/a $2.590 n/a
$440 Announces 1:7 Non-Renounceable Rights Offer 22 Feb 2006 12:25PM $0.104 $2.590 risen by 2,380.84%
$440 Half Yearly Report & Half Year Accounts 22 Feb 2006 12:22PM n/a $2.590 n/a
$440 $400000 Functional Foods Trial 10 Feb 2006 12:51PM $0.109 $2.590 risen by 2,269.62%
$440 Commitments Test Entity - Second Quarter Report 19 Jan 2006 1:40PM n/a $2.590 n/a
$440 $1.28m Pfizer Deal 15 Dec 2005 8:58AM $0.129 $2.590 risen by 1,904.64%
$440 Share Placement 15 Dec 2005 8:53AM $0.129 $2.590 risen by 1,904.64%

951 - 975 of 990 results

Page 39 of 40

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.